Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 3/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.38 |
| ▸ | PRCP | P42785 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4082518 | 0.91 | CTSC (0.42) | CTSCADRB2SLC7A5PRCPOPRD1 | |
| SCHEMBL4086975 | 0.80 | CTSL (0.51) | — | |
| SCHEMBL1645427 | 0.77 | CTSC (0.58) | CTSCSLC7A5OPRD1OPRM1OPRK1 | |
| SCHEMBL9350598 | 0.76 | CTSC (0.57) | CTSCSLC7A5OPRD1OPRM1OPRK1 | |
| SCHEMBL9350595 | 0.76 | CTSC (0.57) | CTSCSLC7A5OPRD1OPRM1OPRK1 | |
| SCHEMBL9637178 | 0.72 | CTSC (0.54) | CTSCSLC7A5OPRD1OPRM1OPRK1 | |
| SCHEMBL9637180 | 0.72 | CTSC (0.54) | CTSCSLC7A5OPRD1OPRM1OPRK1 | |
| SCHEMBL7108845 | 0.70 | SLC7A5 (0.54) | ADRB2SLC7A5NOS3NOS1NOS2 | |
| SCHEMBL21947593 | 0.70 | SLC7A5 (0.54) | ADRB2SLC7A5NOS3NOS1NOS2 | |
| SCHEMBL3770254 | 0.70 | SLC7A5 (0.54) | ADRB2SLC7A5NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | CTSC 619/4885ADRB2 3884/4885SLC7A5 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.